Semiannual Report — FY2026 H1
What Sumitomo Pharma Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-02View the original on EDINET
How much it says
49Typical
What moved here
21named for the first time
Its own wording
33terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, revenue increased, while core operating profit, operating profit and interim profit attributable to owners of the parent all declined. The main factors cited include higher revenue from increased sales of Orgovyx and Gemtesa in the United States and the weaker yen, offset by changes in the product mix following the transfer of part of the interest in the Asia business, increases in promotional and research and development expenses, and the impact of gains on the transfer of interests in associates recorded in the same period of the previous year.
Komori's summary of this document, not the document's own words.49Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
53
Typical
82
Very detailed
62
Detailed
0
Almost nothing
0
Almost nothing
55
Typical
69
Detailed
55
Typical
32
Thin
R&D spend238億円Money spent making new things.
Cash left over172億円Cash from the business, less what went into equipment.
Spent on equipment-7億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.